Recombinant tissue plasminogen activator for the treatment of cutaneous infarctions in antiphospholipid antibody syndrome: A case report

Angiology

Volumn 52, Issue 9, 2001, Pages 635-639

  Srinivasan, Shashi K ^a   Pittelkow, Mark R ^a   Cooper, Leslie T ^b  

^a Department of Dermatology ^*  (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY; WARFARIN;

AGED; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; CASE REPORT; DOSE RESPONSE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INFARCTION; LASER DOPPLER FLOWMETRY; SKIN BLOOD FLOW; THROMBOEMBOLISM; TREATMENT FAILURE; WOUND HEALING;

AGED; ANTIPHOSPHOLIPID SYNDROME; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION; LASER-DOPPLER FLOWMETRY; RECOMBINANT PROTEINS; SKIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034827930     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970105200908     Document Type: Article

References (40)

1. Thrombosis, abortion, cerebral disease and lupus anticoagulant
2. Antiphospholipid antibody syndrome
3. The antiphospholipid and thrombosis syndromes
4. Skin lesions associated with circulating lupus anticoagulant
5. Antiphospholipid antibodies: Lupus anticoagulant and anticardiolipin antibody
6. The spectrum of livedo reticularis and anticardiolipin antibodies
7. Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: A case control study
8. Vasculitis in the antiphospholipid syndrome
9. Livedo vasculitis: Segmental hyalinizing vasculitis of the dermis
10. Lupus anticoagulant and the skin
11. Gangrene as a manifestation of systemic lupus erythematosus
12. Disseminated intravascular coagulation, antiphospholipid antibodies, and ischemic necrosis of extremities
13. Widespread cutaneous necrosis associated with the lupus anticoagulant
14. Cutaneous necrosis associated with lupus anticoagulant
15. Cutaneous manifestations associated with the presence of the lupus anticoagulant
16. Skin nodules and macules resembling vasculitis in the antiphospholipid syndrome: A report of two cases
17. Amaurosis fugax associated with antiphospholipid antibodies
18. Subungual splinter hemorrhages: A new sign of the antiphospholipid coagulopathy?
19. Histopathologic and immunofluorescence study of skin lesions associated with circulating lupus anticoagulant
20. Cutaneous histopathologic finding in "Antiphospholipid Syndrome": Correlation with disease, including human immunodeficiency virus disease
21. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome
22. Arterial thrombosis, intrauterine death, and lupus anticoagulant: Detection of immunoglobulin interfering with prostacyclin formation
23. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation
24. Lupus-like anticoagulants: Modulation of the protein C pathway and thrombosis
25. Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein
26. The fibrinolytic response to venous occlusion and natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus
27. Occlusive vasculopathy in systemic lupus erythematosus: Association with anti-cardiolipin antibody
28. Antiphospholipid syndrome and the skin
29. Antiphospholipid antibodies and cerebral ischemia in young people
30. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: Evidence for a prothrombotic state
31. Thrombotic cutaneous nodules and hepatic vein thrombosis in the anticardiolipin syndrome
32. Corticosteroid-associated blue toe syndrome: Role of antiphospholipid antibodies
33. Splinter haemorrhages in SLE
34. Acro-angiodermatitis: Simulant of Kaposi's sarcoma
35. Antiphospholipid syndrome
36. Clinical trials on antiphospholipid syndrome: What is being done and what is needed?
37. Antiphospholipid antibody-associated thrombosis: A consensus for treatment?
38. The management of thrombosis in the antiphospholipid syndrome
39. Tissue plasminogen activator for treatment of livedoid vasculitis
40. Systemic therapy with fibrinolytic agents and heparin for recalcitrant nonhealing cutaneous ulcer in the antiphospholipid syndrome